Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer

Armando Lucero-Acuña,1 Justin J Jeffery,2 Edward R Abril,3,4 Raymond B Nagle,3,4 Roberto Guzman,1 Mark D Pagel,2,3,5,6 Emmanuelle J Meuillet3,7,8 1Department of Chemical and Environmental Engineering, University of Arizona, 2Department of Biomedical Engineering, University of Arizona, 3...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lucero-Acuña A, Jeffery JJ, Abril ER, Nagle RB, Guzman R, Pagel MD, Meuillet EJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/f91b6ca9c5fd4bbdb5d5c01dae0eb6d5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f91b6ca9c5fd4bbdb5d5c01dae0eb6d5
record_format	dspace
spelling	oai:doaj.org-article:f91b6ca9c5fd4bbdb5d5c01dae0eb6d52021-12-02T00:43:21ZNanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer1178-2013https://doaj.org/article/f91b6ca9c5fd4bbdb5d5c01dae0eb6d52014-12-01T00:00:00Zhttp://www.dovepress.com/nanoparticle-delivery-of-an-aktpdk1-inhibitor-improves-the-therapeutic-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013 Armando Lucero-Acuña,1 Justin J Jeffery,2 Edward R Abril,3,4 Raymond B Nagle,3,4 Roberto Guzman,1 Mark D Pagel,2,3,5,6 Emmanuelle J Meuillet3,7,8 1Department of Chemical and Environmental Engineering, University of Arizona, 2Department of Biomedical Engineering, University of Arizona, 3University of Arizona Cancer Center, 4Department of Pathology, University of Arizona, 5Department of Chemistry and Biochemistry, University of Arizona, 6Department of Medical Imaging, University of Arizona, 7Department of Molecular and Cell Biology, University of Arizona, 8Department of Nutritional Sciences, University of Arizona, Tucson, AZ, USA Abstract: The K-ras mutation in pancreatic cancer can inhibit drug delivery and increase drug resistance. This is exemplified by the therapeutic effect of PH-427, a small molecule inhibitor of AKT/PDK1, which has shown a good therapeutic effect against a BxPC3 pancreatic cancer model that has K-ras, but has a poor therapeutic effect against a MiaPaCa-2 pancreatic cancer model with mutant K-ras. To increase the therapeutic effect of PH-427 against the MiaPaCa-2 pancreatic cancer model with mutant K-ras, we encapsulated PH-427 into poly(lactic-co-glycolic acid) nanoparticles (PNP) to form drug-loaded PH-427-PNP. PH-427 showed a biphasic release from PH-427-PNP over 30 days during studies in sodium phosphate buffer, and in vitro studies revealed that the PNP was rapidly internalized into MiaPaCa-2 tumor cells, suggesting that PNP can improve PH-427 delivery into cells harboring mutant K-ras. In vivo studies of an orthotopic MiaPaCa-2 pancreatic cancer model showed reduced tumor load with PH-427-PNP as compared with treatment using PH-427 alone or with no treatment. Ex vivo studies confirmed the in vivo results, suggesting that PNP can improve drug delivery to pancreatic cancer harboring mutant K-ras. Keywords: nanoparticles, pancreatic cancer, AKT, bioluminescence imaging, drug deliveryLucero-Acuña AJeffery JJAbril ERNagle RBGuzman RPagel MDMeuillet EJDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2014, Iss Issue 1, Pp 5653-5665 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Lucero-Acuña A Jeffery JJ Abril ER Nagle RB Guzman R Pagel MD Meuillet EJ Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer
description	Armando Lucero-Acuña,1 Justin J Jeffery,2 Edward R Abril,3,4 Raymond B Nagle,3,4 Roberto Guzman,1 Mark D Pagel,2,3,5,6 Emmanuelle J Meuillet3,7,8 1Department of Chemical and Environmental Engineering, University of Arizona, 2Department of Biomedical Engineering, University of Arizona, 3University of Arizona Cancer Center, 4Department of Pathology, University of Arizona, 5Department of Chemistry and Biochemistry, University of Arizona, 6Department of Medical Imaging, University of Arizona, 7Department of Molecular and Cell Biology, University of Arizona, 8Department of Nutritional Sciences, University of Arizona, Tucson, AZ, USA Abstract: The K-ras mutation in pancreatic cancer can inhibit drug delivery and increase drug resistance. This is exemplified by the therapeutic effect of PH-427, a small molecule inhibitor of AKT/PDK1, which has shown a good therapeutic effect against a BxPC3 pancreatic cancer model that has K-ras, but has a poor therapeutic effect against a MiaPaCa-2 pancreatic cancer model with mutant K-ras. To increase the therapeutic effect of PH-427 against the MiaPaCa-2 pancreatic cancer model with mutant K-ras, we encapsulated PH-427 into poly(lactic-co-glycolic acid) nanoparticles (PNP) to form drug-loaded PH-427-PNP. PH-427 showed a biphasic release from PH-427-PNP over 30 days during studies in sodium phosphate buffer, and in vitro studies revealed that the PNP was rapidly internalized into MiaPaCa-2 tumor cells, suggesting that PNP can improve PH-427 delivery into cells harboring mutant K-ras. In vivo studies of an orthotopic MiaPaCa-2 pancreatic cancer model showed reduced tumor load with PH-427-PNP as compared with treatment using PH-427 alone or with no treatment. Ex vivo studies confirmed the in vivo results, suggesting that PNP can improve drug delivery to pancreatic cancer harboring mutant K-ras. Keywords: nanoparticles, pancreatic cancer, AKT, bioluminescence imaging, drug delivery
format	article
author	Lucero-Acuña A Jeffery JJ Abril ER Nagle RB Guzman R Pagel MD Meuillet EJ
author_facet	Lucero-Acuña A Jeffery JJ Abril ER Nagle RB Guzman R Pagel MD Meuillet EJ
author_sort	Lucero-Acuña A
title	Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer
title_short	Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer
title_full	Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer
title_fullStr	Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer
title_full_unstemmed	Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer
title_sort	nanoparticle delivery of an akt/pdk1 inhibitor improves the therapeutic effect in pancreatic cancer
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/f91b6ca9c5fd4bbdb5d5c01dae0eb6d5
work_keys_str_mv	AT luceroacuntildeaa nanoparticledeliveryofanaktpdk1inhibitorimprovesthetherapeuticeffectinpancreaticcancer AT jefferyjj nanoparticledeliveryofanaktpdk1inhibitorimprovesthetherapeuticeffectinpancreaticcancer AT abriler nanoparticledeliveryofanaktpdk1inhibitorimprovesthetherapeuticeffectinpancreaticcancer AT naglerb nanoparticledeliveryofanaktpdk1inhibitorimprovesthetherapeuticeffectinpancreaticcancer AT guzmanr nanoparticledeliveryofanaktpdk1inhibitorimprovesthetherapeuticeffectinpancreaticcancer AT pagelmd nanoparticledeliveryofanaktpdk1inhibitorimprovesthetherapeuticeffectinpancreaticcancer AT meuilletej nanoparticledeliveryofanaktpdk1inhibitorimprovesthetherapeuticeffectinpancreaticcancer
_version_	1718403533146947584

Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer

Ejemplares similares